Abstract Library

#4152 Valvular surgery in carcinoid heart disease – Indications and outcome

Introduction: Neuroendocrine tumors (NET) can release biogenic amines that can induce a fibrotic process in the heart valves known as carcinoid heart disease (CHD). Valvular replacement surgery is the standard of care, but such interventions are associated with significant morbidity and valid criteria for both selecting patients (pts) and timing of surgery are limited.

Conference:

Presenting Author:

Authors: Sponheim J, Beitnes J, Dahle G, Åvitsland T, Thiis-Evensen E,

Keywords: carcinoid heart disease, valvular surgery, prognostic factors,

#4118 Adverse events after endoscopic ultrasound-guided fine-needle aspiration and fine-needle biopsy in pancreatic neuroendocrine tumors: A systematic review

Introduction: Pathological analysis of pancreatic neuroendocrine tumors (pNET) is essential for predicting tumor behaviour and patient management. Although endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is the established practice for retrieving tissue, fine-needle biopsy (EUS-FNB) offers possibilities for additional analyses including tumor grading. This systematic review provides a comprehensive evaluation of EUS-FNA and EUS-FNB-related adverse events in pNET.

Conference:

Presenting Author: Chen J

Authors: Chen J, Verschuur A, Abdelmonem A, Dreijerink K, Engelsman A,

Keywords: pancreatic neuroendocrine tumor, EUS-FNA, EUS-FNB, adverse events, systematic review,

#4092 Liver transplantation for neuroendocrine tumor liver metastases: UK and Ireland’s pioneering pilot programme

Introduction: The incidence of neuroendocrine tumours (NETs) continues to rise. Liver metastases (LM) are commonly present at diagnosis. Liver transplantation (LT) has become an applicable treatment for a subset of these patients.

Conference:

Presenting Author: Rehman Z

Authors: Rehman Z, Ford S, Dasari B, Hughes S, El-Shafie M,

Keywords: metastases, transplant, liver, neuroendocrine,

#4065 DAREON™-7: A Phase I, open-label, dose escalation and expansion cohort trial of the delta-like ligand (DLL3)-targeting T-cell engager BI 764532, plus first-line platinum-based chemotherapy in patients with DLL3-positive neuroendocrine carcinomas

Introduction: Neuroendocrine carcinomas (NEC) have limited treatment options. DLL3 is highly expressed on NEC and is a promising treatment target. In an ongoing Phase I trial (NCT04429087), BI 764532, a DLL3/CD3 IgG-like T-cell engager (TcE), was tolerable with promising activity in pretreated pts with DLL3-positive (+) tumours, including NEC.

Conference:

Presenting Author: Capdevila J

Authors: Capdevila J, Vandamme T, Niccoli P, Mishima S, Kato K,

Keywords: neuroendocrine carcinoma, delta-like ligand, T-cell engager, Phase I,

#3932 Artisan: Prospective phase II trial of TheraSphere Selective Internal Radiation Therapy (SIRT) for liver metastases in neuroendocrine tumors (NETs)

Introduction: The liver is the commonest site of metastases and is an independent predictor of poor outcome. SIRT allows delivery of high dose radiation to liver metastases and has shown promise in the management of NETs. We determined the safety and efficacy of SIRT in those with inoperable liver metastases in a prospective study.

Conference:

Presenting Author: Ahmed Q

Authors: Ahmed Q, Doumanoglou N, Evans J, Martinez M, Ward C,

Keywords: radioembolization, carcinoid, neuroendocrine, metastases,